Supernus Pharmaceuticals Inc. Insider Trading

SUPN

Last 12 months

Insiders sold $10.3M and bought nothing on the open market.

82% of the selling was scheduled in advance under 10b5-1 plans. Director Georges Gemayel sold $1M on Mar 6, 41% of their stake, outside a plan. The last open-market buy by an executive or director was in Aug 2019.

Net open-market

−$10.3M

0 buys · 9 sales

Under a 10b5-1 plan

82%

of the value sold

Insiders who bought / sold

0 / 7

executives and directors

Last open-market buy

Aug 2019

Aug 23, 2019

Get an email when SUPN's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Mar 16 – 18	Padmanabh P. Bhatt Sr. VP of IP, CSO	Sold10b5-1 plan 6 parts	107,250	$50.24 average	$5.39M	86%	Form 4
Mar 13	Jack A. Khattar President, CEO	Sold10b5-1 plan 3 parts	35,000	$50.37 average	$1.76M	1.1%	Form 4
Mar 12	Frederick M. Hudson Director	SoldNo plan	5,369	$50.61	272K	8.2%	Form 4
Mar 9 – 10	William Todd Horich SVP, Commercial Operations	SoldNo plan 2 parts	8,877	$54.50 average	484K	100%	Form 4
Mar 9	Frank Mottola SVP, Chief Tech. Ops. Officer	SoldNo plan	1,623	$53.65	87K	8.1%	Form 4
Mar 5 – 6	Georges Gemayel Director	SoldNo plan 2 parts	18,787	$53.38 average	$1M	41%	Form 4
Feb 19	Bethany Sensenig Director	Sold10b5-1 plan 2 parts	4,475	$51.01 average	228K	100%	Form 4
Dec 19, 2025	Frank Mottola SVP, Chief Tech. Ops. Officer	Sold10b5-1 plan 2 parts	20,000	$50.41 average	$1.01M	56%	Form 4
Dec 18, 2025	Padmanabh P. Bhatt Sr. VP of IP, CSO	SoldNo plan	710	$44.44	32K	4.7%	Form 4
Oct 9, 2025	Jack A. Khattar President, CEO	Sold10b5-1 plan 2 parts	59,900	$50.57 average	$3.03M	2.6%	Form 4
Oct 9, 2025	Charles W Newhall III Director	Sold10b5-1 plan 2 parts	25,000	$50.77 average	$1.27M	19%	Form 4
Oct 2, 2025	Jack A. Khattar President, CEO	Sold10b5-1 plan	1,904	$48.06	92K	<0.1%	Form 4
Oct 1, 2025	Jack A. Khattar President, CEO	Sold10b5-1 plan	40,173	$48.07	$1.93M	1.8%	Form 4
Sep 30, 2025	Jack A. Khattar President, CEO	Sold10b5-1 plan	8,588	$48.25	414K	0.4%	Form 4
Sep 29, 2025	Jack A. Khattar President, CEO	Sold10b5-1 plan	10,235	$48.02	491K	0.5%	Form 4
Sep 23, 2025	Jack A. Khattar President, CEO	Sold10b5-1 plan	29,513	$47.23	$1.39M	1.4%	Form 4
Sep 22, 2025	Jack A. Khattar President, CEO	Sold10b5-1 plan	16,587	$47.02	780K	0.8%	Form 4
Sep 12, 2025	Frank Mottola SVP, Chief Tech. Ops. Officer	SoldNo plan	5,000	$45.87	229K	24%	Form 4
Sep 8, 2025	Jack A. Khattar President, CEO	Sold10b5-1 plan	6,322	$46.29	293K	0.6%	Form 4
Sep 5, 2025	Jack A. Khattar President, CEO	Sold10b5-1 plan	55,578	$46.01	$2.56M	2.6%	Form 4
Aug 27, 2025 – Aug 28, 2025	Jack A. Khattar President, CEO	Sold10b5-1 plan 2 parts	34,800	$45.10 average	$1.57M	1.6%	Form 4
Aug 27, 2025	Charles W Newhall III Director	Sold10b5-1 plan	3,588	$45.01	161K	2.7%	Form 4
Aug 25, 2025	Frank Mottola SVP, Quality, GMP, Ops, IT	SoldNo plan	14,000	$44.51	623K	47%	Form 4
Aug 25, 2025	Jack A. Khattar President, CEO	Sold10b5-1 plan	1,000	$45.00	45K	<0.1%	Form 4
Aug 25, 2025	Charles W Newhall III Director	Sold10b5-1 plan	1,000	$45.00	45K	0.7%	Form 4
Aug 22, 2025	Jack A. Khattar President, CEO	Sold10b5-1 plan	1,500	$45.00	68K	<0.1%	Form 4
Aug 22, 2025	Timothy C Dec Senior Vice-President & CFO	SoldNo plan	11,780	$44.49	524K	90%	Form 4
Aug 22, 2025	Charles W Newhall III Director	Sold10b5-1 plan	1,412	$45.00	64K	1.0%	Form 4
Aug 14, 2025	Bethany Sensenig Director	Sold10b5-1 plan	5,369	$42.25	227K	100%	Form 4
Aug 14, 2025	Frederick M. Hudson Director	SoldNo plan	7,457	$42.26	315K	14%	Form 4
Aug 6, 2025	Jack A. Khattar President, CEO	Sold10b5-1 plan 3 parts	140,000	$42.02 average	$5.88M	6.3%	Form 4
Feb 21, 2025	Jonathan Rubin SVP, Chief Medical Officer	SoldNo plan	927	$39.15	36K	7.7%	Form 4
Feb 4, 2025	Padmanabh P. Bhatt Sr. VP of IP, CSO	Sold10b5-1 plan	9,477	$39.70	376K	48%	Form 4
Jan 27, 2025 – Jan 28, 2025	Padmanabh P. Bhatt Sr. VP of IP, CSO	Sold10b5-1 plan 2 parts	3,273	$39.62 average	130K	24%	Form 4
Dec 3, 2024	Padmanabh P. Bhatt Sr. VP of IP, CSO	Sold10b5-1 plan 2 parts	21,495	$36.68 average	788K	69%	Form 4
Nov 11, 2024	Charles W Newhall III Director	SoldNo plan	10,700	$36.24	388K	7.6%	Form 4
Nov 8, 2024	Frederick M. Hudson Director	SoldNo plan	8,722	$36.28	316K	23%	Form 4
Nov 8, 2024	Georges Gemayel Director	SoldNo plan	10,787	$36.30	392K	45%	Form 4
Nov 8, 2024	Jack A. Khattar President, CEO	SoldNo plan	125,000	$36.29	$4.54M	6.0%	Form 4
Nov 7, 2024	Frank Mottola SVP, Quality, GMP, Ops, IT	SoldNo plan	15,000	$36.98	555K	65%	Form 4

Mar 16 – 1810b5-1 plan
Padmanabh P. Bhatt
Sr. VP of IP, CSO · sold 107,250 at avg $50.24
$5.39M
86% of stake
Mar 1310b5-1 plan
Jack A. Khattar
President, CEO · sold 35,000 at avg $50.37
$1.76M
1.1% of stake
Mar 12No plan
Frederick M. Hudson
Director · sold 5,369 at $50.61
272K
8.2% of stake
Mar 9 – 10No plan
William Todd Horich
SVP, Commercial Operations · sold 8,877 at avg $54.50
484K
100% of stake
Mar 9No plan
Frank Mottola
SVP, Chief Tech. Ops. Officer · sold 1,623 at $53.65
87K
8.1% of stake
Mar 5 – 6No plan
Georges Gemayel
Director · sold 18,787 at avg $53.38
$1M
41% of stake
Feb 1910b5-1 plan
Bethany Sensenig
Director · sold 4,475 at avg $51.01
228K
100% of stake
Dec 19, 202510b5-1 plan
Frank Mottola
SVP, Chief Tech. Ops. Officer · sold 20,000 at avg $50.41
$1.01M
56% of stake
Dec 18, 2025No plan
Padmanabh P. Bhatt
Sr. VP of IP, CSO · sold 710 at $44.44
32K
4.7% of stake
Oct 9, 202510b5-1 plan
Jack A. Khattar
President, CEO · sold 59,900 at avg $50.57
$3.03M
2.6% of stake
Oct 9, 202510b5-1 plan
Charles W Newhall III
Director · sold 25,000 at avg $50.77
$1.27M
19% of stake
Oct 2, 202510b5-1 plan
Jack A. Khattar
President, CEO · sold 1,904 at $48.06
92K
<0.1% of stake
Oct 1, 202510b5-1 plan
Jack A. Khattar
President, CEO · sold 40,173 at $48.07
$1.93M
1.8% of stake
Sep 30, 202510b5-1 plan
Jack A. Khattar
President, CEO · sold 8,588 at $48.25
414K
0.4% of stake
Sep 29, 202510b5-1 plan
Jack A. Khattar
President, CEO · sold 10,235 at $48.02
491K
0.5% of stake
Sep 23, 202510b5-1 plan
Jack A. Khattar
President, CEO · sold 29,513 at $47.23
$1.39M
1.4% of stake
Sep 22, 202510b5-1 plan
Jack A. Khattar
President, CEO · sold 16,587 at $47.02
780K
0.8% of stake
Sep 12, 2025No plan
Frank Mottola
SVP, Chief Tech. Ops. Officer · sold 5,000 at $45.87
229K
24% of stake
Sep 8, 202510b5-1 plan
Jack A. Khattar
President, CEO · sold 6,322 at $46.29
293K
0.6% of stake
Sep 5, 202510b5-1 plan
Jack A. Khattar
President, CEO · sold 55,578 at $46.01
$2.56M
2.6% of stake
Aug 27, 2025 – Aug 28, 202510b5-1 plan
Jack A. Khattar
President, CEO · sold 34,800 at avg $45.10
$1.57M
1.6% of stake
Aug 27, 202510b5-1 plan
Charles W Newhall III
Director · sold 3,588 at $45.01
161K
2.7% of stake
Aug 25, 2025No plan
Frank Mottola
SVP, Quality, GMP, Ops, IT · sold 14,000 at $44.51
623K
47% of stake
Aug 25, 202510b5-1 plan
Jack A. Khattar
President, CEO · sold 1,000 at $45.00
45K
<0.1% of stake
Aug 25, 202510b5-1 plan
Charles W Newhall III
Director · sold 1,000 at $45.00
45K
0.7% of stake
Aug 22, 202510b5-1 plan
Jack A. Khattar
President, CEO · sold 1,500 at $45.00
68K
<0.1% of stake
Aug 22, 2025No plan
Timothy C Dec
Senior Vice-President & CFO · sold 11,780 at $44.49
524K
90% of stake
Aug 22, 202510b5-1 plan
Charles W Newhall III
Director · sold 1,412 at $45.00
64K
1.0% of stake
Aug 14, 202510b5-1 plan
Bethany Sensenig
Director · sold 5,369 at $42.25
227K
100% of stake
Aug 14, 2025No plan
Frederick M. Hudson
Director · sold 7,457 at $42.26
315K
14% of stake
Aug 6, 202510b5-1 plan
Jack A. Khattar
President, CEO · sold 140,000 at avg $42.02
$5.88M
6.3% of stake
Feb 21, 2025No plan
Jonathan Rubin
SVP, Chief Medical Officer · sold 927 at $39.15
36K
7.7% of stake
Feb 4, 202510b5-1 plan
Padmanabh P. Bhatt
Sr. VP of IP, CSO · sold 9,477 at $39.70
376K
48% of stake
Jan 27, 2025 – Jan 28, 202510b5-1 plan
Padmanabh P. Bhatt
Sr. VP of IP, CSO · sold 3,273 at avg $39.62
130K
24% of stake
Dec 3, 202410b5-1 plan
Padmanabh P. Bhatt
Sr. VP of IP, CSO · sold 21,495 at avg $36.68
788K
69% of stake
Nov 11, 2024No plan
Charles W Newhall III
Director · sold 10,700 at $36.24
388K
7.6% of stake
Nov 8, 2024No plan
Frederick M. Hudson
Director · sold 8,722 at $36.28
316K
23% of stake
Nov 8, 2024No plan
Georges Gemayel
Director · sold 10,787 at $36.30
392K
45% of stake
Nov 8, 2024No plan
Jack A. Khattar
President, CEO · sold 125,000 at $36.29
$4.54M
6.0% of stake
Nov 7, 2024No plan
Frank Mottola
SVP, Quality, GMP, Ops, IT · sold 15,000 at $36.98
555K
65% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch SUPN, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with SUPN

CompareIntrinsic value

IONSIonis Pharmaceuticals, Inc.

$40.15-0.67%39

CORTCorcept Therapeutics Incorporated

$77.59-5.30%56

COLLCollegium Pharmaceutical Inc.

$23.56-0.72%98

TGTXTG Therapeutics, Inc.

$61.63+1.45%57

BBIOBridgeBio Pharma, Inc.

$77.89+5.21%30

KNSAKiniksa Pharmaceuticals International, plc

$96.12+3.03%71

AXSMAxsome Therapeutics, Inc.

$137.00-1.87%10

HRMYHarmony Biosciences Holdings, Inc.

$34.42-7.04%82

Held by ETFs

SUPN is in 86 US ETFs. The largest of them, with SUPN's weight in each:

Spot a number that looks wrong? Check it in SUPN's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing SUPN

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.